Vitamin D and PMDD: Could Correcting a Deficiency Improve Symptoms?
Vitamin D has become something of a wonder nutrient in recent years. It has been linked to improved immunity, bone health, fatigue, depression and even chronic pain. It is perhaps unsurprising, therefore, that many people living with Premenstrual Dysphoric Disorder (PMDD) wonder whether taking vitamin D supplements might reduce the severe mood changes they experience each month.
A new systematic review and meta-analysis published in 2026 has added to the growing body of research examining this question. The authors concluded that vitamin D supplementation may improve overall premenstrual symptoms, particularly low mood and physical symptoms. While these findings are encouraging, they also highlight just how much we still have to learn about the relationship between vitamin D and hormone-sensitive mood disorders.
The reality is that vitamin D is unlikely to be a cure for PMDD. However, correcting a deficiency may represent one small but worthwhile part of a much broader, personalised approach to treatment.
Why might vitamin D influence PMDD?
Unlike many other menstrual disorders, PMDD is not caused by abnormal hormone levels. Most people with PMDD have perfectly normal concentrations of oestrogen and progesterone throughout the menstrual cycle. Instead, the condition appears to arise because the brain responds abnormally to the normal hormonal fluctuations that occur after ovulation.
Current research suggests that progesterone and its neurosteroid metabolite, allopregnanolone, alter signalling within the GABA system in susceptible individuals. Alongside this, changes in serotonin, dopamine, glutamate, inflammation and stress-response pathways are all thought to contribute to symptom development.
Vitamin D is biologically interesting because it interacts with many of these same systems. Vitamin D receptors are found throughout the brain, particularly within areas involved in emotional regulation. Experimental research suggests that vitamin D influences serotonin synthesis, dopamine signalling, immune function, neuroinflammation, oxidative stress and calcium regulation within nerve cells. Although none of this proves that vitamin D deficiency causes PMDD, it does provide a biologically plausible explanation for why low vitamin D levels might worsen symptoms in some individuals.
What did the new study show?
The review combined data from five randomised controlled trials involving 436 participants who received either vitamin D supplementation or placebo or standard care. When the results were pooled together, vitamin D supplementation was associated with a reduction in overall premenstrual symptom severity, together with improvements in depressive symptoms and several physical symptoms, including pain and discomfort.
Interestingly, the researchers did not find convincing evidence that vitamin D improved anxiety, food cravings or water retention. Vitamin D supplementation was also generally well tolerated, with no significant safety concerns reported across the included studies.
At first glance, these findings seem highly encouraging. However, it is important to look beyond the headline results and consider the quality of the evidence itself.
Why should these results be interpreted cautiously?
One of the strengths of a systematic review is that it combines multiple studies to produce a more reliable estimate of treatment effect. However, this only works well when the studies being combined are reasonably similar.
In this review, the included studies differed considerably. Participants received different doses of vitamin D over varying treatment durations, and researchers used different diagnostic criteria and symptom scoring systems. Baseline vitamin D levels also varied, meaning some participants may have been genuinely deficient while others almost certainly had adequate vitamin D status before treatment even began.
These differences resulted in substantial statistical heterogeneity, making it difficult to determine whether the observed improvements were truly due to vitamin D or reflected differences between the studies themselves. Consequently, the authors graded the certainty of the evidence as very low, meaning future high-quality research could substantially change these conclusions.
An important limitation: PMS is not PMDD
For people living with PMDD, perhaps the biggest limitation of this research is that most participants did not have prospectively confirmed PMDD. Instead, the majority of studies included women with Premenstrual Syndrome (PMS).
Although the two conditions share some symptoms, they are fundamentally different disorders. PMS is common and is often characterised by relatively mild physical or emotional symptoms that do not significantly impair day-to-day functioning. PMDD, by contrast, is a severe neurobiological condition that causes profound cyclical mood changes capable of disrupting work, education, relationships and quality of life. Accurate diagnosis requires prospective daily symptom recording over at least two menstrual cycles.
Because the populations studied were predominantly women with PMS rather than confirmed PMDD, it remains uncertain whether these findings can be applied directly to those with more severe hormone-sensitive mood disorders.
What about vitamin D deficiency?
This distinction is particularly important because there are really two separate clinical questions. The first is whether vitamin D deficiency contributes to worsening symptoms. The second is whether taking additional vitamin D helps people who already have normal vitamin D levels.
Previous research has consistently shown that lower vitamin D levels are associated with more severe premenstrual symptoms. While association alone cannot establish cause and effect, it is entirely plausible that correcting a genuine deficiency could improve overall brain function sufficiently to reduce symptom burden. That is very different, however, from suggesting that high-dose vitamin D supplementation benefits everyone with PMDD regardless of their baseline vitamin D status.
At present, we simply do not have enough evidence to answer that second question confidently.
Should people with PMDD have their vitamin D levels checked?
In clinical practice, assessing vitamin D status can be a reasonable part of a comprehensive evaluation, particularly in individuals who have recognised risk factors for deficiency. These include limited sunlight exposure, darker skin pigmentation, obesity, gastrointestinal disorders affecting absorption, coeliac disease, inflammatory bowel disease and eating disorders.
Vitamin D deficiency is common throughout the UK, especially during the winter months. If deficiency is identified, replacement is recommended for bone health and general wellbeing irrespective of its effect on PMDD. Any improvement in mood symptoms should therefore be regarded as a potential additional benefit rather than the primary reason for treatment.
Is vitamin D a treatment for PMDD?
Based on current evidence, the answer is no. Vitamin D should not be considered a first-line treatment for PMDD, nor should it replace treatments with a much stronger evidence base.
For most people, evidence-based management continues to centre around selective serotonin reuptake inhibitors (SSRIs), ovulation suppression using certain combined hormonal contraceptives, transdermal oestradiol with appropriate endometrial protection, or GnRH analogue therapy in severe cases. Psychological therapies, particularly cognitive behavioural therapy, alongside good sleep, regular exercise and attention to overall health, also form important components of long-term management.
Within this wider framework, vitamin D supplementation may have a role as an adjunctive intervention, particularly where deficiency is present, but the current evidence does not support relying on it as a stand-alone treatment.
The bigger picture
Perhaps the most encouraging aspect of this research is not that it identifies another potential supplement, but that it reflects a broader shift in our understanding of PMDD. Increasingly, researchers recognise that hormone sensitivity exists within a complex biological network involving neurotransmitters, inflammation, sleep, metabolism, nutrition and stress physiology. Optimising any one of these factors is unlikely to eliminate PMDD entirely, but addressing several together may meaningfully reduce the overall burden of symptoms.
For some individuals, correcting vitamin D deficiency may prove to be one valuable piece of that puzzle. The challenge for future research will be identifying which patients are most likely to benefit and whether vitamin D has a specific role in prospectively diagnosed PMDD rather than premenstrual symptoms more generally.
Key take-home messages
Vitamin D supplementation may reduce overall premenstrual symptom severity, particularly depressive and physical symptoms.
The current evidence is based largely on women with PMS rather than prospectively diagnosed PMDD.
The certainty of the evidence remains very low because existing studies are small and highly variable.
Correcting vitamin D deficiency is worthwhile for overall health and may improve symptoms in some individuals.
Vitamin D should currently be viewed as one component of a personalised PMDD management plan rather than a replacement for established treatments.
At Sirona Health, we believe that successful PMDD management requires looking beyond hormones alone. Understanding nutrition, sleep, brain health, co-existing conditions such as ADHD or perimenopause, and individual patterns of hormone sensitivity allows treatment to be tailored to each person rather than relying on a one-size-fits-all approach.
Reference
Zainab A, Tageldin RS, Patel R, Hassan MA, Aburas LA, Alkahily M, Shamsan L, Al-Olaimat SS, Sayeed A, Abu-Zaid A. Efficacy of Vitamin D Supplementation to Alleviate Premenstrual Syndrome Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2026 Jun 22;15(12):4828. doi: 10.3390/jcm15124828. PMID: 42355996; PMCID: PMC13301900.